A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company’s cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug.
In an October 2014 lawsuit, Amgen had sought to stop Paris-based Sanofi and Tarrytown, New York-based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9.
Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California-based company’s patents related to the protein. A jury found Amgen’s patents valid in March.
